Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7797970 | 0.90 | KMT2A (0.42) | SIGMAR1MEN1KMT2A | |
| SCHEMBL8077363 | 0.86 | MEN1 (0.44) | ABCB1ABCG2MEN1KMT2ACARM1 | |
| SCHEMBL7802393 | 0.85 | KMT2A (0.44) | MEN1KMT2ACARM1 | |
| Hydrochloric Acid SCHEMBL7797935 | 0.84 | KMT2A (0.43) | MEN1KMT2ACARM1 | |
| SCHEMBL8184618 | 0.82 | KMT2A (0.46) | SIGMAR1MEN1KMT2A | |
| SCHEMBL8189705 | 0.80 | KDR (0.46) | SIGMAR1ABCB1ABCG2MEN1KMT2A | |
| SCHEMBL7797950 | 0.79 | KDM4E (0.44) | MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8182718 | 0.79 | KDR (0.45) | SIGMAR1ABCB1ABCG2MEN1KMT2A | |
| SCHEMBL8183726 | 0.79 | KMT2A (0.44) | MEN1KMT2AKDR | |
| SCHEMBL8184203 | 0.79 | KMT2A (0.42) | SIGMAR1ABCB1ABCG2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-09-27 | — | — | US | disclosed |
| EP-1025087-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999021836-A1 | SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | SIGMAR1 776/4885ABCB1 235/4885ABCG2 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.